Armgo Pharma
ARMGO Pharma is a privately owned biotech company based in Tarrytown, NY, specializing in the development of first-in-class disease-modifying therapeutics for rare cardiac and skeletal muscle diseases. Their primary focus is on two orphan diseases, Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) and RYR1-Related Myopathy (RYR1-RM), which are caused by genetic mutations in the RYR genes. ARMGO Pharma's molecules, known as Rycals, are designed to repair leaky RyR calcium channels associated with these diseases, offering the potential for disease-modifying therapy.
With an exclusive worldwide license from Columbia University for its RyR technology and know-how, ARMGO Pharma is pioneering world-class science to treat RyR-related diseases. Led by a team of experienced professionals, including Chief Executive Officer Eugene Marcantonio, MD, PhD, and Chief Operating Officer General Counsel Yael Webb, PhD, JD, the company is committed to advancing research and clinical trials to provide innovative solutions for patients suffering from these rare conditions.
Generated from the website
Also at this address
You might also like
Partial Data by Foursquare.
